Strategic foresight


Strategic foresight

26.08.2015 - In August, Thomas Bachmann has taken over the role of CEO at Eppendorf Group. Bachmann has been a member of the Supervisory Board of the German laboratory product and service provider since 2013.

Bachmann has been active in the Life Sciences for ten years. Before switching to Eppendorf, he was President of the Bruker BioSpin Group. Prior to that, he was responsible for the Switzerland-based Tecan Group.


06.08.2015 Cancer immunotherapy play Rigontec GmbH has appointed J. Donald deBethizy as Chairman of the Board of Directors. He replaces Gunther Hartmann, who co-founded the Bonn-based company in early 2014 and will remain on the board.

© Rigontec GmbH

deBethizy brings long years of biotech and R&D experience to the spin-out of Bonn University. He is already serving on the supervisory boards of arGEN-X NV, Newron Pharmaceuticals SPA, Serendex Pharmaceuticals and Noxxon Pharma AG. He is also President of White City Consulting ApS in Denmark.

Previously, deBethizy, who holds MS and PhD degrees in toxicology from Utah State University and a BS in biology from the University of Maryland, served as President and CEO of Santaris Pharma A/S and as Executive Chairman of Contera Pharma. He was also co-founder and CEO of US biotechnology company Targacept Inc.


17.08.2015 While CEO Matthias Schroff and CFO Jörg Petraß have resigned their positions at Mologen AG, the new CEO is already waiting in the wings. In November 2015, Mariola Söhngen will be taking over the reins of the Berlin-based drug developer.

© Paion AG

Söhngen has held the position of Chief Medical Officer of Paion AG, which she also co-founded. At the specialty pharma company, which is listed on Frankfurt Stock Exchange, she was responsible for phase I to IV clinical development, regulatory and approval issues, pharmaceutical drug safety, quality assurance, project management, Human Resources, Intellectual Property as well as preclinical research and development.


17.08.2015 German biotech Brain AG is restructuring its management team. Co-founder Jürgen Eck has taken over as CEO and chairman of the company’s management board in July. Former CEO Holger Zinke has transferred to the supervisory board.

© Brain AG

After completing his doctorate in biochemistry and molecular genetics, Eck was responsible for research and development in the newly founded Brain AG. Since 2000, he has been Chief Technology Offices at the Zwingenberg-based company. He is also one of the co-founders of the Centre for Molecular Biodiversity Research.


06.08.2015 In June, Brigita Tetičkovič took over as Director of Teva Pharmaceutical Industries Ltd’s office in Slovenia. She comes to the Israeli pharma company from Pfizer GEP BU, Slovenia and Bosnia and Herzegovina, where she held the position of Sales Manager.


The doctor of veterinary medicine started out as Product Sales Representative at Pfizer, and has since gathered managerial experience within marketing and sales.

At Teva, Tetičkovič will be responsible for the overall operations of the Slovenian branch office and for its business results.


10.08.2015 UK antibiotics developer Motif Bio plc has appointed infectious diseases expert Thomas File to its Scientific Advisory Board. File is Chair of the Division of Infectious Diseases at Summa Health System, a non-profit integrated healthcare delivery system in the US.

© Motif Bio plc

At Northeast Ohio Medical University, he holds positions as Professor of Internal Medicine and the Chair of the Infectious Disease Section.

Previously, Dr. File served as Past-President and as a member of the Board of Directors for the National Foundation for Infectious Diseases and on the Board of Directors for the Infectious Disease Society of America. In 2010, he was elected as a Faculty Member to the Alpha Omega Alpha Honorary Society and in 2013, was recipient of the Watanakunakorn Clinician Award of the Infectious Diseases Society of America.

With 275 publications in his name, File also serves on the Editorial Boards of Infectious Diseases in Clinical Practice, where he is Editor-in-Chief.


03.08.2015 Finnish health tech group Revenio Group Corporation, listed on NASDAQ OMX Helsinki, has a new Chief Financial Officer. Robin Pulkkinen joins Revenio from his previous position as Symbio Inc.’s VP of Finance.

© Robin Pulkkinen

Prior to Symbio, Pulkkinen held several management positions both in Finland and in Canada. He holds a Master of Economics from Helsinki School of Economics. Pulkkinen has joined Revenio as of July 15, 2015 and reports to the Revenio Group's President and CEO Olli-Pekka Salovaara.



25.07.2015 US-Belgian cancer Dx specialist MDxHealth SA has appointed Philip J. Ginsburg as its new Chief Medical Officer. In this role, Ginsburg will have responsibility for the clinical strategy of the Herstal-based company that provides actionable epigenetic information to personalise the diagnosis and treatment of cancer.

© MDxHealth SA

Before joining MDxHealth, Ginsburg worked as CMO at Toma Biosciences and as President at Arista, a personalised medicine division of Iris International, Inc. later acquired by Beckman. Prior to that, he was CEO and co-founder of molecular Dx lab AlliedPath, which was ultimately acquired by Iris. Ginsburg also served as Senior Medical Director at Gen-Probe, Inc. Dr. Ginsburg earned his medical degree at the University of Pretoria School of Medicine, South Africa, and later specialised in clinical pathology at the University of Witwatersrand and the South African Institute of Medical Research.


28.07.2015 British cancer Dx developer 14M Genomics, a spin-out of the Wellcome Trust Sanger Institute, has appointed Alan Schafer as CEO.

© 14M Genomics

He most recently served as CEO of Population Genetics Technologies, an infectious molecular disease diagnostic company. Previously, he was Global VP of Technology Development at pharma giant GlaxoSmithKline. He co-founded Hexagen, a functional genomics company that was acquired by Incyte where he subsequently served as VP of Genetics. He has also served as Director of Science Funding at the Wellcome Trust.


22.07.2015 June Raine has been confirmed as Chair of the European Pharmacovigilance Risk Assessment Committee (PRAC). At its July 2015 meeting, the committee of the European Medicines Agency voted to prolong the mandate of Raine by another three years.


Raine’s colleague Álmath Spooner was also confirmed as co-chair. Raine holds a PhD and undertook postgraduate research leading to an MSc in pharmacology. Today, she is Director of Vigilance and Risk Management of Medicines at the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK. She has served as chair of the PRAC since September 2012.

Her key priorities for the future of the PRAC are: to evaluate the outcome of its pharmacovigilance activities and decisions in terms of measurable public health benefit; to ensure pharmacovigilance and risk management systems are key enablers of earlier access for patients to innovative medicines; and to continue to progress the way in which the PRAC engages with healthcare professionals, patients and the public to deliver regulatory decisions.


15.07.2015 French clinical stage biotech GenSight Biologics has appointed Thomas Gidoin as Chief Financial Officer. The Paris-based company discovers and develops novel therapies for diseases of the eye. In his new role, Gidoin will be responsible for the company’s future corporate and financial development strategies and operations.

© Thomas Gidoin

Gidoin brings long years of corporate finance and leadership experience to GenSight Biologics SA. From October 2012 to July 2015, he led the Corporate Finance team at DBV Technologies as Vice President Finance. At DBV, he participated in public offerings and private placements, including the dual listing of the company on the NASDAQ Global Select Market.

Prior to that, Gidoin worked at Ipsen, biotech pharma, from 2008 to 2011, as a Senior Financial Analyst and later as UK Operations Controller in London. He holds Master’s degrees in International Finance and in International Management. 

1/28Nächste Seite


All videos

Product of the week



All Events

Stock list

All quotes


  • KARO BIO (S)33.00 SEK2042.86%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • SERODUS (N)2.92 NOK14.51%


  • SYNGENTA (CH)309.90 CHF-18.19%
  • ZELTIA (E)3.35 EUR-12.76%


  • KARO BIO (S)33.00 SEK2015.4%
  • TRANSGENE (F)3.82 EUR29.5%


  • WILEX (D)1.95 EUR-43.6%
  • BIONOR PHARMA (N)1.21 NOK-42.4%
  • NORDIC NANOVECTOR (N)19.40 NOK-29.5%


  • KARO BIO (S)33.00 SEK3828.6%
  • ADOCIA (F)82.74 EUR395.2%
  • GALAPAGOS (B)53.36 EUR313.6%


  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.87 EUR-76.4%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 26.08.2015

Current issue

All issues